Health Management

The healthcare tech company will assist health plans in meeting Care for Older Adults requirements.

Of the 87% of executives who see convergence already happening, 89% say it is accelerating—up from 21% who said the same in 2018.

Early studies from China suggested that CT scans of the lungs could be used to diagnose the disease. But as PCR tests became available, radiology groups said CT scans should be used more sparingly and in confirmed cases.

During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech presented plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.

The two PCSK9 inhibitors have fallen far short of expectations. Inclisiran, which works by RNA inference, only needs to be injected twice a year. 

Pharmacy benefit managers are taking steps to be more responsible for the total cost of care and to become more transparent, while adding technology tools to support patients, payers and physicians in a post-COVID-19 world.

As the pandemic enters its fourth month in the U.S., the Center for Medicare and Medicaid Innovation (the Innovation Center) has announced several changes that, on the whole, increase flexibility for program participants.

Early detection of low blood oxygen levels may detect ‘silent hypoxia’ seen in some patients with COVID-19. But the American Lung Association advises against buying a pulse oximeter unnecessarily.

Will produce recommendations for policymakers on crucial issues for future of remote care services.

Some hospitals were overwhelmed. But for many providers, COVID-19 has meant the absence of patients - and major drops in revenue. And now there is a possible economic downturn. COVID-19 has hit American healthcare and hit it hard.   

Health and healthcare inequities are the most likely explanation for the disproportionate effect.

Understandably, there is a lot of nervousness around how COVID-19 is going to affect the healthcare industry-both in the near-term as well as the distant future. As the organizations that will have to take on a majority of the financial and operational burden of the COVID pandemic, providers will be hit the hardest in the short-term. As a result, a majority of relief, both at federal and local levels, can be expected to be centered around rescuing providers post-COVID.

Despite everything we hear in the news lately, there is a silver lining to the Covid-19 cloud. For certain, the landscape of the Addiction Treatment Industry has changed and arguably, the old ways of doing business are no longer sustainable in this environment.

Filling a void left by the Trump Administration, the Association for Community Affiliated Plans (ACAP) recently announced a campaign to remind Americans who need health insurance because of the COVID-19 that they may be eligible for coverage through healthcare.gov.

Drug makers around the world are racing to develop the first effective COVID-19 vaccine. Early efforts show promise, but an anticipated jump in the novel coronavirus cases in the fall means the sooner a vaccine is developed, the more lives can be saved-and the pharmaceutical industry plays a major role in this discovery.

Three new scientific theories explaining that although autoimmune disease affects both genders, women are at an overwhelming disadvantage.

As the U.S. begins reopening, potentially sparking a “second wave” of COVID-19 cases, hospitals and health systems will need to continue operating in a state of high-stress readiness.

Nothing can bring a healthcare system to its knees quite like a pandemic. What COVID-19 is leaving in its wake is a new respect for numbers - for accurate data that can predict new threats, track current ones and trigger an avalanche of innovative responses.

As COVID-19 has spread around the world, data has shown that those with weakened immune systems are among the most susceptible to severe illness from the virus.

Amid considerable uncertainty in healthcare, quality care coordination is largely within your own control and can make an immensely positive impact on those you serve.

Dwindling reliance on primary care physicians is burdening healthcare system and limiting care resources.

The Institute for Clinical and Economic Review (ICER) found siponimod has benefits for patients with active secondary progressive multiple sclerosis, but its benefits were in line with other therapies in a crowded marketplace.

Much remains unknown about how precisely multiple sclerosis occurs and advances in patients, but a growing body of research is helping scientists develop new ways to slow, and potentially stop, disease progression.

For those of us who spend our lives and careers fighting to improve care for individuals with the most significant medical, social and behavioral health needs, a study that found disappointing results from a well-regarded model will not deter us, but only reinforce the power and necessity of our endeavor.

Anesthesia practices see major financial hit as physician anesthesiologists pivot during COVID-19 to treat patients in critical care and ICUs, ASA survey highlights.

Jeffrey Skolnik, MD, vice president, clinical development of Inovio Pharmaceuticals Inc Discusses Glioblastoma Treatment in ASCO interview.

Adrian Kilcoyne MD MBA MPH, vice president, US Medical Affairs and HEOR, oncology, AstraZeneca, discusses a paradigm shift in lung cancer treatment due to the overwhelming efficacy of the EGFR-TKI treatment.